The regenerative activity of interleukin-6

Methods in Molecular Biology

Volumn 982, Issue , 2013, Pages 59-77

  Galun, Eithan ^a   Rose John, Stefan ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Gp130; Inflammation; Interleukin 6; Interleukin 6 receptor; Regeneration; Shedding; Soluble interleukin 6 receptor; STAT3; Stem cells

Indexed keywords

ACUTE PHASE PROTEIN; GLYCOPROTEIN GP 130; HYBRID PROTEIN; HYPERINTERLEUKIN 6; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG; STAT3 PROTEIN;

ARTICLE; B LYMPHOCYTE ACTIVATION; HUMAN; INFLAMMATION; LIVER REGENERATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REGENERATIVE MEDICINE; SIGNAL TRANSDUCTION; TISSUE REGENERATION; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; REGENERATION; STEM CELL;

ANIMALS; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; REGENERATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STEM CELLS;

EID: 84880360495     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-308-4_4     Document Type: Article

References (129)

1. Hirano T et al (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76
2. Bazan JF (1990) Haemopoietic receptors and helical cytokines. Immunol Today 11: 350-354
3. Yamasaki K et al (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241: 825-828
4. Hibi M et al (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149-1157
5. Heinrich PC et al (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20
6. Scheller J et al (2006) Updating IL-6 classicand trans-signaling. Signal Transduct 6: 240-259
7. Rose-John S et al (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236
8. Jones S et al (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121: 3375-3383
9. Campard D et al (2006) Multilevel regulation of IL-6R by IL-6-sIL-6R fusion protein according to the primitiveness of peripheral blood-derived CD133+ cells. Stem Cells 24: 1302-1314
10. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300(Pt 2): 281-290
11. Romano M et al (1997) Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315-325
12. Müllberg J et al (1993) The soluble interleukin- 6 receptor is generated by shedding. Eur J Immunol 23: 473-480
13. Müllberg J et al (1992) Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun 189: 794-800
14. Dimitrov S et al (2006) Sleep enhances IL-6 trans-signaling in humans. FASEB J 20(12): 2174-2176
15. Scheller J et al (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32: 380-387
16. Althoff K et al (2001) Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J 353: 663-672
17. Althoff K et al (2000) Shedding of interleukin- 6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 267: 2624-2631
18. Matthews V et al (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278: 38829-38839
19. Mullberg J et al (1995) A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 155: 5198-5205
20. Black RA et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor- alpha from cells. Nature 385: 729-733
21. Moss ML et al (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733-736
22. Rose-John S, Schooltink H (2007) Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 174: 57-66
23. Grotzinger J et al (1999) IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 380: 803-813
24. Grotzinger J et al (1997) The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 27: 96-109
25. Fischer M et al (1997) I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15: 142-145
26. Galun E et al (2000) Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 14: 1979-1987
27. Peters M et al (2000) Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 119: 1663-1671
28. Marz P et al (1998) Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A 95: 3251-3256
29. Marz P et al (1999) Neural activities of IL-6- type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 11: 2995-3004
30. Islam O et al (2009) Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell 20: 188-199
31. Klouche M et al (1999) Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 163: 4583-4589
32. Audet J et al (2001) Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc Natl Acad Sci U S A 98: 1757-1762
33. Baiocchi M et al (2000) An IL-6/IL-6 soluble receptor (IL-6R) hybrid protein (H-IL-6) induces EPO-independent erythroid differentiation in human CD34(+) cells. Cytokine 12: 1395-1399
34. Hieronymus T et al (2008) The transcription factor repertoire of Flt3+ hematopoietic stem cells. Cells Tissues Organs 188: 103-115
35. Hieronymus T et al (2005) Progressive and controlled development of mouse dendritic cells from Flt3+CD11b+ progenitors in vitro. J Immunol 174: 2552-2562
36. Ding X et al (2012) Polycomb group protein bmi1 promotes hematopoietic cell development from embryonic stem cells. Stem Cells Dev 21: 121-132
37. Hacker C et al (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4: 380-386
38. Sere KM et al (2011) Dendritic cell lineage commitment is instructed by distinct cytokine signals. Eur J Cell Biol 91: 515-523
39. Humphrey RK et al (2004) Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells 22: 522-530
40. Viswanathan S et al (2002) Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell selfrenewal responses to LIF and HIL-6. Stem Cells 20: 119-138
41. Jostock T et al (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167
42. Nowell MA et al (2003) Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171: 3202-3209
43. Nowell MA et al (2009) Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 182: 613-622
44. Richards PJ et al (2006) Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 54: 1662-1672
45. Hurst SM et al (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714
46. Barkhausen T et al (2011) Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 39: 1407-1413
47. Greenhill CJ et al (2011) IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 186: 1199-1208
48. Atreya R et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583-588
49. Mitsuyama K et al (2006) STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55: 1263-1269
50. Becker C et al (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501
51. Becker C et al (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4: 217-220
52. Matsumoto S et al (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184: 1543-1551
53. Lo CW et al (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71: 424-434
54. Lesina M et al (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469
55. Scheller J et al (2011) The pro- and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813: 878-888
56. Heinrich PC et al (1990) Interleukin-6 and the acute phase response. Biochem J 265: 621-636
57. Bollrath J et al (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102
58. Grivennikov S et al (2009) IL-6 and STAT3 signaling is required for survival of intestinal epithelial cells and colitis associated cancer. Cancer Cell 16: 103-113
59. Ernst M, Jenkins BJ (2004) Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20: 23-32
60. Smith AG et al (1988) Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 336: 688-690
61. Matsuda T et al (1999) STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J 18: 4261-4269
62. Ying QL et al (2008) The ground state of embryonic stem cell self-renewal. Nature 453: 519-523
63. Cressman DE et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274: 1379-1383
64. Hecht N et al (2001) Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Ther 3: 683-687
65. Nechemia-Arbely Y et al (2011) Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. J Hepatol 54: 922-929
66. Nechemia-Arbely Y et al (2008) IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19: 1106-1115
67. Chalaris A et al (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207: 1617-1624
68. Garbers C et al (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin- 6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 286: 14804-14811
69. Chalaris A et al (2007) Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110: 1748-1755
70. Matsushita K et al (2005) Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 85: 1210-1223
71. Malato Y et al (2011) Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 121: 4850-4860
72. Mitchell C, Willenbring H (2008) A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 3: 1167-1170
73. Jackson LN et al (2008) PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 294:G1401-G1410
74. Maione D et al (1998) Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 17: 5588-5597
75. Schirmacher P et al (1998) Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 153: 639-648
76. Peters M et al (1998) In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 161: 3575-3581
77. Drucker C et al (2009) Interleukin-6 transsignaling regulates glycogen consumption after D -galactosamine-induced liver damage. J Interferon Cytokine Res 29: 711-718
78. Riehle KJ et al (2008) Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 205: 91-103
79. Markiewski MM et al (2009) The regulation of liver cell survival by complement. J Immunol 182: 5412-5418
80. Peters M et al (1997) Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 185: 755-766
81. Peters M et al (1996) The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183: 1399-1406
82. Schooltink H et al (1991) Structural and functional studies on the human hepatic interleukin- 6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J 277(Pt 3): 659-664
83. Hanna JH (2010) The STATs on naive iPSC reprogramming. Cell Stem Cell 7: 274-276
84. Stuhlmann-Laeisz C et al (2006) Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell 17: 2986-2995
85. Serrano AL et al (2008) Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 7: 33-44
86. Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translationalfindings, and therapeutic implications for cardiac disease. Circ Res 109: 923-940
87. Lam SP et al (2010) Activation of interleukin- 6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transpl 16: 1195-1206
88. Yeoh GC et al (2007) Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology 45: 486-494
89. Gotze KS et al (2001) gp130-stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. Exp Hematol 29: 822-832
90. Kimura T et al (2000) Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors. Stem Cells 18: 444-452
91. Ellingsgaard H et al (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105: 13163-13168
92. Dierssen U et al (2008) Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. J Biol Chem 283: 9886-9895
93. Streetz KL et al (2003) Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology 125: 532-543
94. Wuestefeld T et al (2003) Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem 278: 11281-11288
95. Wuestefeld T et al (2005) Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology 42: 1082-1090
96. Klein C et al (2005) The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 115: 860-869
97. Tiberio GA et al (2008) IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy. Cytokine 42: 372-378
98. Tiberio GA et al (2007) Interleukin-6 sustains hepatic regeneration in cirrhotic rat. Hepatogastroenterology 54: 878-883
99. Gewiese-Rabsch J et al (2010) Role of IL-6 trans-signaling in CCl induced liver damage. Biochim Biophys Acta 1802: 1054-1061
100. Jin X et al (2007) Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 46: 802-812
101. Zhu BM et al (2008) SOCS3 negatively regulates the gp130-STAT3 pathway in mouse skin wound healing. J Invest Dermatol 128: 1821-1829
102. Hilfiker-Kleiner D et al (2005) Many good reasons to have STAT3 in the heart. Pharmacol Ther 107: 131-137
103. Katare R et al (2011) Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 108: 1238-1251
104. Chablais F et al (2011) The zebrafish heart regenerates after cryoinjury-induced myocardial infarction. BMC Dev Biol 11:21
105. Jopling C et al (2010) Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 464: 606-609
106. Schnabel K et al (2011) Regeneration of cryoinjury induced necrotic heart lesions in zebrafish is associated with epicardial activation and cardiomyocyte proliferation. PLoS One 6:e18503
107. Porrello ER et al (2011) Transient regenerative potential of the neonatal mouse heart. Science 331: 1078-1080
108. Cai CL et al (2008) A myocardial lineage derives from Tbx18 epicardial cells. Nature 454: 104-108
109. Zhou B et al (2008) Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454: 109-113
110. Bergmann O et al (2009) Evidence for cardiomyocyte renewal in humans. Science 324: 98-102
111. Bolli R et al (2011) A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 50: 589-597
112. Huang C et al (2011) SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 301:H1496-H1505
113. Hirota H et al (1999) Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97: 189-198
114. Hilfiker-Kleiner D et al (2004) Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95: 187-195
115. Drenger B et al (2011) Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinasemediated inhibition. Anesthesiology 114: 1364-1372
116. Glass C, Singla DK (2011) MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. Am J Physiol Heart Circ Physiol 301:H2038-H2049
117. Rajesh KG et al (2005) Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway. J Mol Cell Cardiol 39: 766-776
118. Takahama H et al (2006) Granulocyte colony- stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3- kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 20: 159-165
119. Smith PD et al (2009) SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron 64: 617-623
120. Sun F et al (2011) Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature 480: 372-375
121. Cafferty WB et al (2001) Leukemia inhibitory factor determines the growth status of injured adult sensory neurons. J Neurosci 21: 7161-7170
122. Cao Z et al (2006) The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. J Neurosci 26: 5565-5573
123. Miao T et al (2006) Suppressor of cytokine signaling- 3 suppresses the ability of activated signal transducer and activator of transcription-3 to stimulate neurite growth in rat primary sensory neurons. J Neurosci 26: 9512-9519
124. Benigni A et al (2010) Kidney regeneration. Lancet 375: 1310-1317
125. Homsi E et al (2002) Interleukin-6 stimulates tubular regeneration in rats with glycerolinduced acute renal failure. Nephron 92: 192-199
126. Boswell RN et al (1994) Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant 9: 599-606
127. Feliers D, Kasinath BS (2011) Erk in kidney diseases. J Signal Transduct 2011:768512
128. Skiniotis G et al (2008) Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol Cell 31: 737-748
129. Müller P et al (2008) Identification of JAK/STAT pathway regulators-insights from RNAi screens. Semin Cell Dev Biol 19: 360-369